Align Technology Stock (ALGN)

XNGS Alert Compare

Health Care · Fundamental analysis

· How we analyze

Metrics from daily candles, as of Nov 20, 2026 · Extended universe

Figures in the price bar from TradingView (mostly trailing 12 months) · our fundamental analysis uses the fiscal year

Preset: moving averages 50 and 200 (on the daily chart the 50- and 200-day lines), plus volume. You can add further indicators in the chart yourself. Preset: moving averages 50 and 200 (on the daily chart the 50- and 200-day lines), plus volume. You can add further indicators in the chart yourself. Academy: 200-day line · RSI

About the company

Align Technology makes clear dental aligners under the Invisalign brand, which are used to straighten teeth. The company also sells iTero intraoral scanners and software to dentists and orthodontists worldwide. As of Oct 11, 2026

Fact sheet (from the annual report) Orthopedic and surgical supplies · Tempe, USA

Align Technology designs, manufactures and markets clear aligners under the Invisalign brand for correcting misaligned teeth. It also offers iTero intraoral scanners and exocad design software for dental labs and dentists. Its segments are called Clear Aligner and Imaging Systems and CAD/CAM Services. The company sells most products directly through a specialized sales force to orthodontists, dentists and dental labs, and in some countries also through agents and distributors. Through a monthly subscription (Invisalign Doctor Subscription Program), practices receive retainers and aligners for minor touch-up corrections.

Automatically summarized from SEC annual report (10-K, filed Feb 27, 2026) (website of the US Securities and Exchange Commission) · reviewed Oct 15, 2026

Price performance at a glance

Last 30 trading days
  • Today −2.8%
  • 7 days −7.8%
  • 30 days +2.5%
  • 1 year +16.9%
Day range (last trading day)
−0.5%Price at 9% of the range+4.5%
52-week range
−14.5%Price at 33% of the range+29.1%
Distance from the all-time high
−79.0%

Our own calculation from the exchange’s daily candles, as of Nov 20, 2026. “All-time” applies since the start of this series, not to the whole market. Changes in percent; the TradingView chart shows prices. “Today” = change of the last trading day versus the previous day. Not investment advice.

Fundamentals · Analysis method

Growth, margin, balance sheet, cash flow and dividend compared with the sector – with traffic lights and quality checks in the fundamental analysis. To the fundamental analysis

Fundamental analysis

Align Technology · Sector Health Care · amounts in USD

Source: SEC filings, As of Feb 27, 2026.

For you first Dividend

The company pays no dividend.

For you first Valuation

The P/E is about at its own median of the 5 fiscal years before.

With a free account you can see how far – and the same for P/S and price/free cash flow, with the calculation. Sign up free

For you first Growth

How strongly revenue and earnings per share have grown over the years.

Check “Growth”
5 of 7
criteria with data met
Revenue per year (5 y)
+10.3%
EPS per year (5 y)
−24.1%

For you first Quality

How much of revenue remains and whether profit arrives as cash.

Check “Quality”
6 of 8
criteria with data met
Net margin
10.2%
Cash flow ÷ profit
1.45x
backed from 1.0 · 3 years: 1.66x

For you first Trading

The overview of this stock shows the trend by timeframe.

Quality checks

Four angles on the annual figures. Each check counts how many disclosed criteria are met – criteria without data do not count. The bars show where the company ranks on each figure among the stocks we cover and within its sector.

Fiscal year to Dec 31, 2025

Quality 6 of 8 met

  • met: Gross margin above 40% 67.2%
  • not met: Operating margin above 15% 13.5%
  • met: Net margin above 10% 10.2%
  • not met: Return on equity above 15% 10.1%
  • met: Free cash flow margin above 10% 12.2%
  • met: Profit in each of the last 5 fiscal years 5 of 5
  • met: Free cash flow positive in each of the last 3 fiscal years 3 of 3
  • met: Equity ratio above 30% 65.0%
Gross margin

67.2% Fiscal year 2025

Rank 78 of 100: higher than 78% of 370 peers (All). strong.

Rank 64 of 100: higher than 64% of 49 peers (Sector). medium.

Median Health Care: 61.8%

Share of revenue left after the direct cost of the products sold.

Operating margin

13.5% Fiscal year 2025

Rank 45 of 100: higher than 45% of 470 peers (All). medium.

Rank 44 of 100: higher than 44% of 54 peers (Sector). medium.

Median Health Care: 17.0%

Operating income divided by revenue: what the core business earns before interest and taxes.

Net margin

10.2% Fiscal year 2025

Rank 44 of 100: higher than 44% of 584 peers (All). medium.

Rank 47 of 100: higher than 47% of 63 peers (Sector). medium.

Median Health Care: 12.9%

Profit after all costs, interest and taxes divided by revenue.

Return on equity

10.1% Fiscal year 2025

Rank 38 of 100: higher than 38% of 544 peers (All). medium.

Rank 32 of 100: higher than 32% of 54 peers (Sector). weak.

Median Health Care: 12.8%

Net income divided by equity at fiscal year end.

Return on assets

6.6% Fiscal year 2025 (total assets at year end)

Rank 61 of 100: higher than 61% of 594 peers (All). medium.

Rank 50 of 100: higher than 50% of 63 peers (Sector). medium.

Median Health Care: 6.6%

Net income divided by total assets at fiscal year end.

Equity ratio

65.0% Fiscal year 2025

Rank 87 of 100: higher than 87% of 595 peers (All). strong.

Rank 79 of 100: higher than 79% of 63 peers (Sector). strong.

Median Health Care: 44.2%

Equity as a share of total assets. Usually low for banks.

Free cash flow margin

12.2% Fiscal year 2025

Rank 51 of 100: higher than 51% of 465 peers (All). medium.

Rank 35 of 100: higher than 35% of 61 peers (Sector). medium.

Median Health Care: 14.5%

Free cash flow divided by revenue.

Free cash flow

490.8M USD Fiscal year 2025

Operating cash flow minus capital expenditure on property and equipment.

Growth 5 of 7 met

  • not met: Over 3 years, revenue grew by more than 5% per year +2.6%
  • met: Over 5 years, revenue grew by more than 5% per year +10.3%
  • met: Over 10 years, revenue grew by more than 5% per year +16.9%
  • met: Over 3 years, EPS grew by more than 5% per year +7.0%
  • not met: Over 5 years, EPS grew by more than 5% per year −24.1%
  • met: Revenue rose in at least 4 of the last 5 fiscal years 4 of 5
  • met: Revenue rose in the last fiscal year +0.9%
Revenue growth 3 years

+2.6% per year

Rank 32 of 100: higher than 32% of 578 peers (All). weak.

Rank 40 of 100: higher than 40% of 62 peers (Sector). medium.

Median Health Care: +5.1%

Average growth per year over 3 fiscal years.

Revenue growth 5 years

+10.3% per year

Rank 59 of 100: higher than 59% of 549 peers (All). medium.

Rank 61 of 100: higher than 61% of 60 peers (Sector). medium.

Median Health Care: +7.8%

Average growth per year over 5 fiscal years.

Revenue growth 10 years

+16.9% per year

Rank 87 of 100: higher than 87% of 412 peers (All). strong.

Rank 83 of 100: higher than 83% of 50 peers (Sector). strong.

Median Health Care: +9.3%

Average growth per year over 10 fiscal years.

EPS growth 3 years

+7.0% per year

Rank 48 of 100: higher than 48% of 437 peers (All). medium.

Rank 56 of 100: higher than 56% of 54 peers (Sector). medium.

Median Health Care: +5.0%

Growth of earnings per share per year, adjusted for stock splits.

EPS growth 5 years

−24.1% per year

Rank 2 of 100: higher than 2% of 399 peers (All). weak.

Rank 1 of 100: higher than 1% of 47 peers (Sector). weak.

Median Health Care: +8.3%

Growth of earnings per share per year, adjusted for stock splits.

EPS growth 10 years

+12.3% per year

Rank 62 of 100: higher than 62% of 375 peers (All). medium.

Rank 58 of 100: higher than 58% of 46 peers (Sector). medium.

Median Health Care: +9.3%

Growth of earnings per share per year, adjusted for stock splits.

Dividend 0 of 1 met · 6 without data

  • not met: Pays a dividend no dividend per share reported for the last fiscal year
  • no data: Payout ratio at most 60% of earnings pays no dividend
  • no data: Dividend paid in each of the last 5 fiscal years pays no dividend
  • no data: Dividend per share never lowered in the last 5 fiscal years pays no dividend
  • no data: Dividend per share higher than 5 years ago pays no dividend
  • no data: Free cash flow per share covers the dividend pays no dividend
  • no data: Dividends paid over the last 5 years covered by free cash flow pays no dividend

Financial strength 4 of 5 met · 1 without data

  • not met: Piotroski F-Score at least 7 of 9 5 of 8 · 1 without data
  • no data: Long-term debt no higher than equity no long-term debt reported
  • met: Current assets cover current liabilities 1.36
  • met: Positive equity 4.0B USD
  • met: In 5 years, share count up by at most 5% −8.4%
  • met: Free cash flow positive in the last fiscal year 490.8M USD
Piotroski F-Score

5 of 8 Fiscal year 2025

No rank: not all 9 criteria have data.

Nine yes/no tests on profit, cash flow, debt, liquidity and efficiency compared with the prior year.

Liquidity (current ratio)

1.36 at fiscal year end

Rank 53 of 100: higher than 53% of 513 peers (All). medium.

Rank 36 of 100: higher than 36% of 63 peers (Sector). medium.

Median Health Care: 1.58

Current assets divided by current liabilities.

Change in share count

−8.4% in 5 years

Rank 70 of 100: lower than 70% of 507 peers (All). strong.

Rank 69 of 100: lower than 69% of 59 peers (Sector). strong.

Median Health Care: −4.3%

Change in diluted share count. Negative = share buybacks, positive = new shares.

The 9 criteria of the Piotroski F-Score
  • met: Profit in the last fiscal year (positive return on assets)
  • met: Positive operating cash flow
  • not met: Return on assets higher than the prior year
  • met: Operating cash flow higher than net income
  • no data: Long-term debt relative to total assets fell
  • met: Liquidity (current assets / current liabilities) rose
  • met: No additional shares (diluted share count did not rise)
  • not met: Gross margin higher than the prior year
  • not met: Revenue relative to total assets higher than the prior year

Last fiscal year compared with the one before. Returns and revenue per total assets use total assets at the start of the year; leverage = long-term financial debt divided by total assets at year end; new shares via the average diluted share count.

Price-based criteria (P/E, dividend yield) are shown to signed-in users.

Computed automatically from SEC annual reports – not investment advice. Describes the reported figures; points are not a rating of the stock. Rank 0–100 against the 239 stocks we cover and against the sector (from 5 peers); the stronger side is always on the right.

In short

  • Light green: Revenue grew over 5 years (+10.3% per year), at least as fast as the sector median.
  • Light red: Net income (total) shrank over 5 years (−25.4% per year); per share −24.1% per year.
  • Light yellow: Net margin 10.2%, below the sector median (13.9%).
  • Light green: Profit in each of the last 10 fiscal years.

Summarized from the lights below. Describes the reported figures – not a recommendation to buy or sell.

RevenueNet income Net margin (below) in USD
  1. Fiscal year 2016 (Jan 1, 2016 – Dec 31, 2016): Revenue 1.1B USD · Net income 189.7M USD · Net margin 17.6%
  2. Fiscal year 2017 (Jan 1, 2017 – Dec 31, 2017): Revenue 1.5B USD · Net income 231.4M USD · Net margin 15.7%
  3. Fiscal year 2018 (Jan 1, 2018 – Dec 31, 2018): Revenue 2.0B USD · Net income 400.2M USD · Net margin 20.4%
  4. Fiscal year 2019 (Jan 1, 2019 – Dec 31, 2019): Revenue 2.4B USD · Net income 442.8M USD · Net margin 18.4%
  5. Fiscal year 2020 (Jan 1, 2020 – Dec 31, 2020): Revenue 2.5B USD · Net income 1.8B USD · Net margin 71.8%
  6. Fiscal year 2021 (Jan 1, 2021 – Dec 31, 2021): Revenue 4.0B USD · Net income 772.0M USD · Net margin 19.5%
  7. Fiscal year 2022 (Jan 1, 2022 – Dec 31, 2022): Revenue 3.7B USD · Net income 361.6M USD · Net margin 9.7%
  8. Fiscal year 2023 (Jan 1, 2023 – Dec 31, 2023): Revenue 3.9B USD · Net income 445.1M USD · Net margin 11.5%
  9. Fiscal year 2024 (Jan 1, 2024 – Dec 31, 2024): Revenue 4.0B USD · Net income 421.4M USD · Net margin 10.5%
  10. Fiscal year 2025 (Jan 1, 2025 – Dec 31, 2025): Revenue 4.0B USD · Net income 410.4M USD · Net margin 10.2%

Fiscal year 2025 (Jan 1, 2025 – Dec 31, 2025): Revenue 4.0B USD · Net income 410.4M USD · Net margin 10.2%

How has it gone since the last annual report?

Trailing 12 months and quarters

Revenue in the quarter to Sep 2026 +1.9% vs. the same quarter a year earlier; grown for 5 quarters in a row.

Revenue 12 months vs. prior 12
+4.4%
12 months: 4.2B USD · Fiscal year 2025: +0.9%
Net margin 12 months
11.8%
Fiscal year 2025: 10.2%
Free cash flow margin 12 months
14.5%
Fiscal year 2025: 12.2%
More depth

Calculation of the 12 months to Sep 30, 2026

  • Revenue: fiscal year to Dec 31, 2025 4.0B USD + year to date to Sep 30, 2026 3.1B USD − same period a year earlier to Sep 30, 2025 3.0B USD = 4.2B USD
  • Net income: fiscal year to Dec 31, 2025 410.4M USD + year to date to Sep 30, 2026 356.1M USD − same period a year earlier to Sep 30, 2025 274.6M USD = 491.9M USD
  • Operating cash flow: fiscal year to Dec 31, 2025 593.2M USD + year to date to Sep 30, 2026 526.7M USD − same period a year earlier to Sep 30, 2025 370.0M USD = 749.9M USD
  • Capital expenditure: fiscal year to Dec 31, 2025 102.4M USD + year to date to Sep 30, 2026 111.5M USD − same period a year earlier to Sep 30, 2025 66.5M USD = 147.4M USD
By quarter (latest first, amounts in USD)
QuarterRevenuevs. year agoNet incomeMargin
Jul–Sep 261.0B+1.9%135.0M13.3%
Apr–Jun 261.1B+4.3%108.3M10.3%
Jan–Mar 261.0B+6.2%112.8M10.8%
Oct–Dec 25*1.0B+5.3%135.8M13.0%
Jul–Sep 25995.7M+1.8%56.8M5.7%
Apr–Jun 251.0B−1.6%124.6M12.3%
Jan–Mar 25979.3M−1.8%93.2M9.5%
Oct–Dec 24*995.2M+4.0%103.8M10.4%

Trailing 12 months = last fiscal year + the period since the start of the current fiscal year − the same period a year earlier, each from the first filing. P/E, PEG and the quality checks still use the last fiscal year.

Each quarter is compared with the same quarter a year earlier.

* derived: fiscal year minus the first 9 months.

As of: 12 months to Sep 30, 2026, filed on Nov 4, 2026 · Source: SEC filings (10-Q, 10-K)

Does the profit arrive as cash?

Earnings quality

Profit is backed by cash.

Cash flow ÷ profit
1.45x
backed from 1.0 · 3 years: 1.66x
Interest coverage
–
interest expense for FY 2025 not found as a separate figure in the SEC data
Tax rate
29.9%
for information only · 3 years: 30.4%
More depth

Calculation for fiscal year 2025

  • Operating cash flow 593.2M USD ÷ Net income 410.4M USD = 1.45x
  • Taxes 174.9M USD ÷ profit before tax 585.3M USD = 29.9%
By fiscal year
FYCash flow ÷ profitInterest coverageTax rate
20251.45x–29.9%
20241.75x–30.8%
20231.77x–30.6%
20221.57x–39.6%
20211.52x–23.7%

How it is rated: cash flow ÷ profit from 1.0 “backed by cash”, below 0.8 “profit well above the cash coming in”; interest coverage from 5 “well covered”, below 2 “thinly covered”. The tax rate is only shown.

Cash flow ÷ profit uses group profit incl. minority interests, because cash flow also covers the whole group. Profit before tax as reported to the SEC, otherwise approximated. “3 years” = sums of the last three fiscal years – only if every year is reported and the figures have the same origin; for cash flow only with a profit in every year.

As of fiscal year 2025 · Source: SEC filings

How even were the last years?

Consistency

In 10 fiscal years no loss year and one year with lower revenue.

Loss years
0 of 10
net income below zero
Years with lower revenue
1 of 10
revenue below the prior year
Net margin range
62.2 percentage points
from 9.7% to 71.8%
Net margin by fiscal year · ▾ revenue below the prior year
More depth
By fiscal year
FYRevenue vs. prior yearNet margin
2025+0.9%10.2%
2024+3.5%10.5%
2023+3.4%11.5%
2022−5.5%9.7%
2021+59.9%19.5%
2020+2.7%71.8%
2019+22.4%18.4%
2018+33.5%20.4%
2017+36.4%15.7%
2016+27.7%17.6%

Loss year: net income below zero. Lower revenue: revenue below the prior year. Range: highest minus lowest net margin; margins beyond ±200% do not count. No score – only the reported figures.

As of fiscal years 2016–2025 · Source: SEC filings

Figures over time

Where the money of a fiscal year goes and how margins, returns, balance sheet, cash flow and share count developed over up to 10 years. Each chart has one sentence saying what the trend shows.

Money flow in fiscal year 2025

Of 100 USD of revenue, 67.2 USD gross profit, 13.5 USD operating income and 10.2 USD net income remained.

Money flow as a table
Fiscal year 2025, amounts in USD, share of revenue
ItemAmountof revenue
Revenue4.0B USD100.0%
Gross profit2.7B USD67.2%
Cost of revenue1.3B USD32.8%
Operating income545.8M USD13.5%
Research & development369.9M USD9.2%
Other operating expenses1.8B USD44.5%
Net income410.4M USD10.2%
Taxes, interest & other (net)135.4M USD3.4%

Taxes, interest and other items are not available separately in the SEC data; they are combined as the difference.

Margins

The operating margin fell in 5 years from 15.7% to 13.5%.

Gross marginOperating marginNet margin
  1. Fiscal year 2016: Gross margin 75.5% · Operating margin 23.1% · Net margin 17.6%
  2. Fiscal year 2017: Gross margin 75.8% · Operating margin 24.0% · Net margin 15.7%
  3. Fiscal year 2018: Gross margin 73.6% · Operating margin 23.7% · Net margin 20.4%
  4. Fiscal year 2019: Gross margin 72.5% · Operating margin 22.5% · Net margin 18.4%
  5. Fiscal year 2020: Gross margin 71.3% · Operating margin 15.7% · Net margin 71.8%
  6. Fiscal year 2021: Gross margin 74.3% · Operating margin 24.7% · Net margin 19.5%
  7. Fiscal year 2022: Gross margin 70.5% · Operating margin 17.2% · Net margin 9.7%
  8. Fiscal year 2023: Gross margin 70.1% · Operating margin 16.7% · Net margin 11.5%
  9. Fiscal year 2024: Gross margin 70.0% · Operating margin 15.2% · Net margin 10.5%
  10. Fiscal year 2025: Gross margin 67.2% · Operating margin 13.5% · Net margin 10.2%

Returns

Return on equity fell in 5 years from 54.9% to 10.1%.

Return on equityReturn on assets
  1. Fiscal year 2016: Return on equity 19.1% · Return on assets 13.6%
  2. Fiscal year 2017: Return on equity 20.1% · Return on assets 13.0%
  3. Fiscal year 2018: Return on equity 31.9% · Return on assets 19.5%
  4. Fiscal year 2019: Return on equity 32.9% · Return on assets 17.7%
  5. Fiscal year 2020: Return on equity 54.9% · Return on assets 36.8%
  6. Fiscal year 2021: Return on equity 21.3% · Return on assets 13.0%
  7. Fiscal year 2022: Return on equity 10.0% · Return on assets 6.1%
  8. Fiscal year 2023: Return on equity 12.3% · Return on assets 7.3%
  9. Fiscal year 2024: Return on equity 10.9% · Return on assets 6.8%
  10. Fiscal year 2025: Return on equity 10.1% · Return on assets 6.6%

Equity and long-term debt

The equity ratio fell in 5 years from 67.0% to 65.0%.

Equity in USD Long-term debt, depending on the filing, includes the current portion or leases.
  1. Fiscal year 2016: Equity 995.4M USD
  2. Fiscal year 2017: Equity 1.2B USD
  3. Fiscal year 2018: Equity 1.3B USD
  4. Fiscal year 2019: Equity 1.3B USD
  5. Fiscal year 2020: Equity 3.2B USD
  6. Fiscal year 2021: Equity 3.6B USD
  7. Fiscal year 2022: Equity 3.6B USD
  8. Fiscal year 2023: Equity 3.6B USD
  9. Fiscal year 2024: Equity 3.9B USD
  10. Fiscal year 2025: Equity 4.0B USD

Liquidity (current ratio)

The current ratio stayed roughly the same in 5 years (1.36).

Current ratio
  1. Fiscal year 2016: Current ratio 2.69
  2. Fiscal year 2017: Current ratio 2.32
  3. Fiscal year 2018: Current ratio 1.88
  4. Fiscal year 2019: Current ratio 1.68
  5. Fiscal year 2020: Current ratio 1.40
  6. Fiscal year 2021: Current ratio 1.30
  7. Fiscal year 2022: Current ratio 1.26
  8. Fiscal year 2023: Current ratio 1.18
  9. Fiscal year 2024: Current ratio 1.22
  10. Fiscal year 2025: Current ratio 1.36

Cash flow

Free cash flow stayed roughly the same in 5 years (490.8M USD).

Operating cash flowCapital expenditureFree cash flow in USD
  1. Fiscal year 2016: Operating cash flow 247.7M USD · Capital expenditure 70.6M USD · Free cash flow 177.1M USD
  2. Fiscal year 2017: Operating cash flow 438.5M USD · Capital expenditure 195.7M USD · Free cash flow 242.8M USD
  3. Fiscal year 2018: Operating cash flow 554.7M USD · Capital expenditure 223.3M USD · Free cash flow 331.4M USD
  4. Fiscal year 2019: Operating cash flow 747.3M USD · Capital expenditure 149.7M USD · Free cash flow 597.6M USD
  5. Fiscal year 2020: Operating cash flow 662.2M USD · Capital expenditure 154.9M USD · Free cash flow 507.3M USD
  6. Fiscal year 2021: Operating cash flow 1.2B USD · Capital expenditure 401.1M USD · Free cash flow 771.4M USD
  7. Fiscal year 2022: Operating cash flow 568.7M USD · Capital expenditure 291.9M USD · Free cash flow 276.8M USD
  8. Fiscal year 2023: Operating cash flow 785.8M USD · Capital expenditure 177.7M USD · Free cash flow 608.1M USD
  9. Fiscal year 2024: Operating cash flow 738.2M USD · Capital expenditure 115.6M USD · Free cash flow 622.7M USD
  10. Fiscal year 2025: Operating cash flow 593.2M USD · Capital expenditure 102.4M USD · Free cash flow 490.8M USD

Share count

The share count fell in 5 years by 8.4% (mostly through share repurchases).

Diluted share count
  1. Fiscal year 2016: Diluted share count 81.5M
  2. Fiscal year 2017: Diluted share count 81.8M
  3. Fiscal year 2018: Diluted share count 81.4M
  4. Fiscal year 2019: Diluted share count 80.1M
  5. Fiscal year 2020: Diluted share count 79.2M
  6. Fiscal year 2021: Diluted share count 79.7M
  7. Fiscal year 2022: Diluted share count 78.4M
  8. Fiscal year 2023: Diluted share count 76.6M
  9. Fiscal year 2024: Diluted share count 75.0M
  10. Fiscal year 2025: Diluted share count 72.6M

From annual reports filed with the SEC (10-K, 20-F, 40-F) as first reported, share count adjusted for splits; obvious filing errors (e.g. wrong unit, outliers against both neighbouring years) are hidden. Describes the reported figures – not investment advice.

Metrics chart

Up to three metrics stacked over the same fiscal years – so you see at a glance whether they rise together or drift apart. Point at a year to read it in every panel.

Metrics, up to 3 – to switch, deselect one first

Premium Line of a second stock for comparison

Net margin

The net margin fell in 5 years from 71.8% to 10.2%.

ALGN Sector today 13.2% Mark in the latest year: today’s median of the Health Care sector as in the sector comparison (each latest fiscal year). We do not have earlier medians.
  1. Fiscal year 2016: ALGN 17.6%
  2. Fiscal year 2017: ALGN 15.7%
  3. Fiscal year 2018: ALGN 20.4%
  4. Fiscal year 2019: ALGN 18.4%
  5. Fiscal year 2020: ALGN 71.8%
  6. Fiscal year 2021: ALGN 19.5%
  7. Fiscal year 2022: ALGN 9.7%
  8. Fiscal year 2023: ALGN 11.5%
  9. Fiscal year 2024: ALGN 10.5%
  10. Fiscal year 2025: ALGN 10.2% · Sector today 13.2%

Return on equity

Return on equity fell in 5 years from 54.9% to 10.1%.

ALGN Sector today 13.6%
  1. Fiscal year 2016: ALGN 19.1%
  2. Fiscal year 2017: ALGN 20.1%
  3. Fiscal year 2018: ALGN 31.9%
  4. Fiscal year 2019: ALGN 32.9%
  5. Fiscal year 2020: ALGN 54.9%
  6. Fiscal year 2021: ALGN 21.3%
  7. Fiscal year 2022: ALGN 10.0%
  8. Fiscal year 2023: ALGN 12.3%
  9. Fiscal year 2024: ALGN 10.9%
  10. Fiscal year 2025: ALGN 10.1% · Sector today 13.6%

Free cash flow margin

The free cash flow margin fell in 5 years from 20.5% to 12.2%.

ALGN Sector today 14.7%
  1. Fiscal year 2016: ALGN 16.4%
  2. Fiscal year 2017: ALGN 16.5%
  3. Fiscal year 2018: ALGN 16.9%
  4. Fiscal year 2019: ALGN 24.8%
  5. Fiscal year 2020: ALGN 20.5%
  6. Fiscal year 2021: ALGN 19.5%
  7. Fiscal year 2022: ALGN 7.4%
  8. Fiscal year 2023: ALGN 15.7%
  9. Fiscal year 2024: ALGN 15.6%
  10. Fiscal year 2025: ALGN 12.2% · Sector today 14.7%

Source: SEC filings, fiscal years up to Dec 31, 2025. The same figures as in the sections of this page, per fiscal year as first reported. Describes the reported figures – not investment advice.

How reliable is the dividend?

Dividend at a glance

The company pays no dividend.

As of fiscal year 2025 · Source: SEC filings

Valued higher or lower than usual?

Valuation against its own history

The P/E is about at its own median of the 5 fiscal years before.

With a free account you can see how far – and the same for P/S and price/free cash flow, with the calculation. Sign up free

Source: SEC filings and our daily candles

Dividends and share repurchases

How much the company returns to its shareholders – as dividends or by repurchasing its own shares – and whether free cash flow supports it.

Dividend per share
none pays no dividend
To shareholders (5 years)
2.2B USD 100% through repurchases
Share count over 5 years
−8.4% fewer shares – each share is a larger stake

What goes back to shareholders

Over 5 years, 2.2B USD went back to shareholders, 100% of it through share repurchases. That is 80% of the free cash flow of those years. This was offset by new shares issued for 125.4M USD (including employee plans).

Dividends paidShare repurchasesNew shares issued (including employee plans)Free cash flow in USD
  1. Fiscal year 2016: Dividends paid not available · Share repurchases 96.2M USD · New shares issued (including employee plans) 13.8M USD · Free cash flow 177.1M USD
  2. Fiscal year 2017: Dividends paid not available · Share repurchases 103.8M USD · New shares issued (including employee plans) 14.5M USD · Free cash flow 242.8M USD
  3. Fiscal year 2018: Dividends paid not available · Share repurchases 300.0M USD · New shares issued (including employee plans) 16.6M USD · Free cash flow 331.4M USD
  4. Fiscal year 2019: Dividends paid not available · Share repurchases 400.0M USD · New shares issued (including employee plans) 17.9M USD · Free cash flow 597.6M USD
  5. Fiscal year 2020: Dividends paid not available · Share repurchases 0.0 USD · New shares issued (including employee plans) 20.3M USD · Free cash flow 507.3M USD
  6. Fiscal year 2021: Dividends paid not available · Share repurchases 375.0M USD · New shares issued (including employee plans) 25.6M USD · Free cash flow 771.4M USD
  7. Fiscal year 2022: Dividends paid not available · Share repurchases 435.0M USD · New shares issued (including employee plans) 26.1M USD · Free cash flow 276.8M USD
  8. Fiscal year 2023: Dividends paid not available · Share repurchases 592.4M USD · New shares issued (including employee plans) 26.6M USD · Free cash flow 608.1M USD
  9. Fiscal year 2024: Dividends paid not available · Share repurchases 352.9M USD · New shares issued (including employee plans) 25.3M USD · Free cash flow 622.7M USD
  10. Fiscal year 2025: Dividends paid not available · Share repurchases 465.9M USD · New shares issued (including employee plans) 21.7M USD · Free cash flow 490.8M USD

Dividends paid, repurchases and new shares issued from the cash flow statement of annual reports filed with the SEC (as first reported). Describes the reported figures – not investment advice.

Valuation over time

Price-based valuation (P/E, P/S, price/free cash flow and dividend yield per fiscal year, compared with its own average) for signed-in users.

Sector comparison

Align Technology next to 8 stocks of the sector Health Care we cover that are closest in revenue. Click a column header to sort the table.

Sector comparison ALGN, sector Health Care; last row: sector median
Symbol Revenue (FY) Growth 5 yrsGross marginOp. marginNet marginROEEquity ratioFCF marginPiotroski
GILD Gilead Sciences 29.4B USD +3.6%78.8%34.0%28.9%37.5%38.5%32.1%8/9
SYK Stryker Corporation 25.1B USD +11.8%64.0%19.5%12.9%14.5%46.9%17.1%6/9
DHR Danaher Corporation 24.6B USD +2.0%59.1%19.1%14.7%6.9%62.9%21.4%7/9
REGN Regeneron Pharmaceuticals 14.3B USD +11.0%–24.9%31.4%14.4%77.1%28.4%–
VRTX Vertex Pharmaceuticals 12.0B USD +14.1%86.2%34.8%32.9%21.2%72.8%26.6%–
ISRG Intuitive Surgical 10.1B USD +18.2%66.0%29.3%28.4%16.0%87.1%24.7%–
ALGN Align Technology this stock 4.0B USD +10.3%67.2%13.5%10.2%10.1%65.0%12.2%–
MRNA Moderna 1.9B USD +19.3%55.3%−158.1%−145.2%−32.6%70.1%−106.2%2/9
NVAX Novavax 1.1B USD +18.8%93.5%40.3%39.2%–−10.9%−22.3%5/9
Median of the sector 27 symbols 44.3B USD +9.4%67.2%17.8%13.2%13.6%38.5%14.7%7/9

Growth 5 yrs = revenue growth per year over 5 fiscal years · Op. margin = operating margin · ROE = return on equity · FCF = free cash flow · Piotroski = F-Score (only with all 9 criteria).

Compare with the closest peer in the sector ALGN next to MRNA – quality checks, metrics and depth side by side.

Figures of the last fiscal year from SEC annual reports (peers as of Nov 22, 2026). Median across all companies of the sector we cover (from 5 stocks; several share classes of one company count once). Signed-in users also see P/E, P/S and dividend yield in the comparison. Describes the reported figures – not investment advice.

Key figures with traffic lights

Each light follows a simple, disclosed rule. The comparison is with the sector median of all 26 symbols in the Health Care sector on our list (current members of the S&P 500 and other lists).

Revenue growth

Light green: above sector

+10.3% per year, last 5 years

Sector Health Care: median +8.5% (25 symbols)

What does this mean? Revenue: over 5 years it grew by 10.3% per year on average – at least as fast as the median company in the sector (+8.5%).

Light rule: Green: grows at least as fast as the sector median (without a sector comparison: grows) · Yellow: grows more slowly · Red: shrinks.

Net income (total)

Light red: shrinking

−25.4% per year, last 5 years

Sector Health Care: median +5.5% (20 symbols)

per share: −24.1% per year (5 years, split-adjusted)

What does this mean? Total net income: over 5 years it fell by 25.4% per year on average. The median company in the sector reached +5.5% per year.

Light rule: Green: grows at least as fast as the sector median (without a sector comparison: grows) · Yellow: grows more slowly · Red: shrinks.

Net margin

Light yellow: below sector

10.2% last fiscal year

Sector Health Care: median 13.9% (26 symbols)

What does this mean? Of every 100 USD in revenue, 10.17 USD remained as profit – less than the median company in the sector (13.9%). Five years ago the margin was 71.8%.

Light rule: Green: at least the sector median (without a sector comparison: profit) · Yellow: profit, but below the median · Red: loss.

Debt / equity

Light gray: not available

– latest balance sheet

Sector Health Care: median 0.66 (19 symbols)

What does this mean? No usable figure: reported financial debt or positive equity for the same balance sheet date is missing.

Light rule: Green: at most the sector median · Yellow: up to twice the median · Red: more than twice · Gray: without a sector comparison.

Payout ratio

Light gray: none found

– Dividend / earnings per share

Sector Health Care: median 56% (16 symbols)

What does this mean? The loaded SEC filings of the last two fiscal years contain no dividend per share. Either the company pays none, or it reports it under a different tag.

Light rule: Green: up to 60% of earnings · Yellow: up to 100% · Red: more than earnings or a dividend despite a loss · Gray for real estate (REITs). The sector median is for comparison only.

Profitable years

Light green: profit every year

10 of 10 fiscal years with a profit

What does this mean? In 10 of the last 10 fiscal years the bottom line showed a profit. There were no losses in this period.

Light rule: Green: profit in every year · Yellow: one loss year · Red: several loss years (at least 3 years needed).

Last fiscal year and 13F

Information, not a trading signal · Source: SEC EDGAR
Revenue (FY)
4.0B USD
Revenue vs. prior year
+0.9%
Net income (FY)
410.4M USD
Net income vs. prior year
−2.6%
EPS (FY)
5.65 USD
Superinvestors holding
2 of 26
Fiscal year to Dec 31, 2025 · 10-K filed Feb 27, 2026 · Price-based figures (P/E, P/S, dividend yield, market cap) only when logged in. · Values as first reported; debt = reported financial debt (US GAAP: long-term). Superinvestors: 26 tracked investors per 13F filing (as of quarter end, filed up to 45 days later); weight and change per investor in the card “Which superinvestors hold …?”.
All figures as a table
Fiscal years (amounts in USD, per share in USD)
YearEndRevenueNet income MarginEarnings per shareDividend per sharePayout
2025Dec 31, 2025 4.0B410.4M 10.2% 5.65 – –
2024Dec 31, 2024 4.0B421.4M 10.5% 5.62 – –
2023Dec 31, 2023 3.9B445.1M 11.5% 5.81 – –
2022Dec 31, 2022 3.7B361.6M 9.7% 4.61 – –
2021Dec 31, 2021 4.0B772.0M 19.5% 9.69 – –
2020Dec 31, 2020 2.5B1.8B 71.8% 22.41 – –
2019Dec 31, 2019 2.4B442.8M 18.4% 5.53 – –
2018Dec 31, 2018 2.0B400.2M 20.4% 4.92 – –
2017Dec 31, 2017 1.5B231.4M 15.7% 2.83 – –
2016Dec 31, 2016 1.1B189.7M 17.6% 2.33 – –
Quarters (amounts in USD, per share in USD)
QuarterEndRevenueNet income MarginEarnings per shareDividend per sharePayout
Q3/26Sep 30, 2026 1.0B135.0M 13.3% 1.90 – –
Q2/26Jun 30, 2026 1.1B108.3M 10.3% 1.51 – –
Q1/26Mar 31, 2026 1.0B112.8M 10.8% 1.57 – –
Q4/25*Dec 31, 2025 1.0B135.8M 13.0% – – –
Q3/25Sep 30, 2025 995.7M56.8M 5.7% 0.78 – –
Q2/25Jun 30, 2025 1.0B124.6M 12.3% 1.72 – –
Q1/25Mar 31, 2025 979.3M93.2M 9.5% 1.27 – –
Q4/24*Dec 31, 2024 995.2M103.8M 10.4% – – –
Q3/24Sep 30, 2024 977.9M116.0M 11.9% 1.55 – –
Q2/24Jun 30, 2024 1.0B96.6M 9.4% 1.28 – –
Q1/24Mar 31, 2024 997.4M105.0M 10.5% 1.39 – –
Q4/23*Dec 31, 2023 956.7M124.0M 13.0% – – –

* Q4 derived: fiscal year minus the 9-month value (EPS cannot be derived this way); may be distorted by restatements.

How we calculate: values as first reported to the SEC (later corrections are left out), a fixed order of reporting tags per figure, partial sums are never added up. Growth per year over 5 years (otherwise 3 years). Quarters are labeled by the calendar quarter in which they end.

Information only – does not affect the other analysis methods, not investment advice.

Insiders

All insider transactions
Insider purchases and sales on the market over 3, 6 and 12 months
PeriodPurchasesSalesNet
3 months $00 people $00 people $0
6 months $00 people $00 people $0
12 months $00 people $1.5M1 person −$1.5M

Latest transactions

  • Feb 18, 2026 Morici John Chief financial officer (CFO) Open-market sale 7,969 shares · $1.5M · SEC

Source: mandatory filings with the SEC (Form 4), open-market purchases and sales only. General information, not investment advice.

Which superinvestors hold Align Technology?

All superinvestor portfolios

2 of 26 tracked superinvestors report a position.

Superinvestors with a position in Align Technology, weight in each portfolio
InvestorWeight in portfoliovs. previous quarterAs of
Bridgewater Associates < 0.1% +32.5% increased Q3 2026
Cathie Wood ARK Investment Management < 0.1% +3.9% increased Q3 2026

Sold out in the latest quarter: Paul Tudor Jones.

Source: 13F filing with the US Securities and Exchange Commission, latest filing dated Nov 16, 2026. It shows positions at quarter end and is filed up to 45 days later – today the positions may be several months old. It covers only securities traded on US exchanges, without short positions; securities traded only abroad and cash are not included.

Trend score –

We do not calculate a trend score for symbols in the extended universe.

Volatility and trend strength

ADX 14 (trend strength)–
Price change 60 days–

ATR and moving averages as price values only when logged in.

More stocks from Health Care

All symbols in this sector

News

No recent news found. News is loaded automatically three times a day for trend stocks, symbols with a current Elliott setup and favorites.

Posts

No posts on ALGN yet – log in to join the discussion.

Posts are opinions of users and only visible after logging in. Community rules

Set alert: ALGN

Alerts with a free account: we send you an email as soon as the price moves above or below your level.

Checked after every data update: crypto hourly, stocks twice a day, precious metals every 4 hours on trading days, extended universe on weekdays after the close (daily candles) – not in real time.

↑ ↓ select · Enter open · Esc close